Press releases

Filter by year

  • Jul 13, 2022
    The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighte…
  • Jul 07, 2022
    Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County
  • Jul 05, 2022
    Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of…
  • May 15, 2022
    Urovant Sciences® presents new data from EMPOWUR study, advancing knowledge of the treatment of overactive bladder at the 2022 Ame…
  • May 13, 2022
    Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tol…
  • Apr 19, 2022
    Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® (Vibegron) 75mg in…
  • Apr 13, 2022
    Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data fr…
  • Apr 04, 2022
    Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer
  • Mar 22, 2022
    Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladd…
  • Mar 07, 2022
    Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902